ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
about
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an exampleInflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsPharmacologic therapy for inflammatory bowel disease refractory to steroidsReview article: biosimilars are the next generation of drugs for liver and gastrointestinal diseasesExperience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesClinical considerations for biosimilar antibodies.Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in GastroenterologyTen years of biosimilars in Europe: development and evolution of the regulatory pathways.Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi PanelNomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.Cost-effectiveness of Crohn's disease post-operative careThe Role of Biosimilars in Inflammatory Bowel Disease.Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel diseaseTargeting TNF-α for the treatment of inflammatory bowel disease.Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.An update on medical management on Crohn's disease.Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.Biosimilars in rheumatology: current perspectives and lessons learnt.Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.CT-P13 in the treatment of rheumatoid arthritis.Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima.Biosimilars in Crohn's Disease and Ulcerative Colitis.Biosimilars and the extrapolation of indications for inflammatory conditions.A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.Position of the Canadian Association of Gastroenterology on subsequent entry biologics is challenged by biosimilar industry representatives.A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.
P2860
Q26766368-D73E7EE5-7066-4633-BCA1-0FA390BCEC8AQ26785537-94A3496B-657C-43A2-B3E3-5A5D85FAEE8FQ26796415-0D999911-AEB8-44AA-A047-B2F158C9F5F2Q27013577-153F9BA5-1880-447B-98E7-A9875DE8A2F6Q28066776-76892D71-0D1B-479A-A9F6-EAEDBD3318DAQ30377239-2126CFB6-183C-4F1A-B963-AD0BA1271A2AQ30393052-068741CB-0FCE-4EFD-A5A1-32B83A1A7C90Q30675199-A551D6BA-3E93-4C00-A55F-57523C9FF485Q33636715-59414C0C-879E-4D42-AD2C-77D5CDE1710DQ33713947-440FDDFB-D73B-4BE5-805E-A32F4F4E3A81Q33740641-6FAB01D8-7F5E-4F26-9CBF-8B12E6A35B10Q35225411-7213C181-8080-45A9-B097-56EC636D440BQ36747868-408CF3CD-8BA5-4318-92B9-2B632F5EA213Q37540190-98B004FD-ADE0-462B-AFB7-3DF58A58BFC0Q37719806-37D49A3F-F360-4E1C-8213-084CC6DE05EFQ38160905-457E06DF-585E-4AC6-8241-B94831F545EFQ38223249-9C0F2CEA-0CC4-4F5B-B5AA-8DD97DEAA5DBQ38270674-CE1D9F92-5994-463E-BDF5-4CD40566F4E3Q38365041-C5F4AE94-41E2-4D6B-A781-8562AF1E91E9Q38394272-15E2BC94-B1AB-4415-87AF-657BB67DC1ACQ38568463-5796D08A-B57A-4503-B141-21048F51E2F0Q38586029-345A859A-6AB2-44A4-B3E3-2CDBE410CBC2Q38609741-ED97D0D3-4D1F-4FBF-B7EC-88566CEA260EQ38676104-D78FB9BB-3108-432A-9D21-3E5023079371Q38686396-F0A84291-962F-4BED-995D-3E6501C20CD9Q38736575-7C862BF5-EB26-4B4F-A195-F5DB6FFEBD4CQ38757671-9620EA56-9A7F-48BC-976A-CE0588E9AE44Q38932150-5BDA573C-EB5E-4644-B7D3-30DC3D10A3A8Q38937842-89B46FA8-3EA6-4013-B0CC-024A92506135Q38960108-6D0000A5-6EB4-4247-955B-AEBAB3E034EEQ39016810-2BB3A448-55DC-4971-B6AE-7BDD6399C818Q39018436-C0F555ED-63E4-4B26-AA11-CC744F5BA083Q40897367-E6DF2C56-DCD4-408D-8D30-87471C6A4A6BQ42962750-CEC4B5AA-7449-4847-AEF2-6CF06058F635Q43926604-57D9B0E3-1A36-4E5A-9309-1272E6A6C1C7Q47368079-D9C45B56-8A54-4080-8931-7DE031C4D736Q48217871-75F5E5C6-3635-465E-8E0A-C73BA5DD6501Q49979586-D4DC58CE-2308-4EB9-9E3C-FFBDFBD55CD8Q50073683-9B2FDE35-D53B-4130-98FD-0638FE7F158AQ50079741-6C0BD783-865B-4A6B-84A5-84A9BE9E0DF5
P2860
ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
ECCO position statement: the u ...... lammatory bowel disease (IBD).
@en
ECCO position statement: the u ...... of inflammatory bowel disease
@nl
type
label
ECCO position statement: the u ...... lammatory bowel disease (IBD).
@en
ECCO position statement: the u ...... of inflammatory bowel disease
@nl
prefLabel
ECCO position statement: the u ...... lammatory bowel disease (IBD).
@en
ECCO position statement: the u ...... of inflammatory bowel disease
@nl
P2860
P1476
ECCO position statement: the u ...... lammatory bowel disease (IBD).
@en
P2093
Governing Board and Operational Board of ECCO
Silvio Danese
P2860
P304
P356
10.1016/J.CROHNS.2013.03.011
P577
2013-04-25T00:00:00Z